Mébutate D'ingénol

Mébutate D'ingénol Uses, Dosage, Side Effects, Food Interaction and all others data.

Mébutate D'ingénol was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including warts and cancer. PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations.

The pharmacodynamics of ingenol mebutate in producing cell death in actinic keratosis is unknown.

Trade Name Mébutate D'ingénol
Generic Ingenol mebutate
Ingenol mebutate Other Names Ingenol mebutate, Ingenol mebutato, Ingenoli mebutas, Mébutate d'ingénol, Mebutato de ingenol
Type
Formula C25H34O6
Weight Average: 430.541
Monoisotopic: 430.235538815
Protein binding

There is no plasma protein binding quantity since ingenol mebutate is a topical treatment

Groups Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Mébutate D'ingénol
Mébutate D'ingénol

Uses

Mébutate D'ingénol is a topical agent used for the treatment of actinic keratosis.

For the topical treatment of actinic keratosis.

Mébutate D'ingénol is also used to associated treatment for these conditions: Actinic Keratosis (AK)

How Mébutate D'ingénol works

The exact mechanism of action of ingenol mebutate in actinic keratosis is unknown. It is presumed to involve primary necrosis then neutrophil-mediated inflammation and antibody-dependent cell death of residual disease cells. Additionally in early studies, PEP005 was shown to be an effective activator of PKC-delta and PKC-delta translocation into nucleus and membranes. PEP005 also downregulates the expression and activity of PKC-alpha. PEP005 induced modulation of PKCs leads to Ras/Raf/MAPK and p38 activation and AKT/PKB inhibition.

Toxicity

The most common adverse reactions are local skin reactions at the application site, headache, periorbital edema,and nasopharyngitis.

Food Interaction

  • Take with or without food.

Volume of Distribution

There is no volume of distribution quantity since ingenol mebutate is a topical treatment.

Elimination Route

Since ingenol mebutate is a topical treatment, the systemic absorption is less than 0.1 ng/mL.

Half Life

There is no half-life quantity since ingenol mebutate is a topical treatment.

Clearance

There is no clearance quantity since ingenol mebutate is a topical treatment.

Elimination Route

There is no route of elimination since ingenol mebutate is a topical treatment.

Innovators Monograph

You find simplified version here Mébutate D'ingénol

*** Taking medicines without doctor's advice can cause long-term problems.
Share